◆英語タイトル:Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA8010459
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月27日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Karyopharm Therapeutics Inc (KPTI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-350, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.
Karyopharm Therapeutics Inc Key Recent Developments
Nov 02,2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
Sep 12,2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 08,2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
May 04,2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress
Apr 03,2017: Karyopharm Announces Management Change
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Karyopharm Therapeutics Inc – Key Facts 6
Karyopharm Therapeutics Inc – Key Employees 7
Karyopharm Therapeutics Inc – Key Employee Biographies 8
Karyopharm Therapeutics Inc – Major Products and Services 9
Karyopharm Therapeutics Inc – History 10
Karyopharm Therapeutics Inc – Company Statement 11
Karyopharm Therapeutics Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
Karyopharm Therapeutics Inc – Business Description 15
R&D Overview 15
Karyopharm Therapeutics Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
Karyopharm Therapeutics Inc – Strengths 16
Karyopharm Therapeutics Inc – Weaknesses 17
Karyopharm Therapeutics Inc – Opportunities 18
Karyopharm Therapeutics Inc – Threats 19
Karyopharm Therapeutics Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28
Karyopharm Therapeutics Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress 30
Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 33
Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress 35
May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress 36
Apr 03, 2017: Karyopharm Announces Management Change 39
Nov 07, 2016: Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress 40
Sep 12, 2016: Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development 42
Aug 04, 2016: Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress 43
May 09, 2016: Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress 45
Apr 06, 2016: Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider 47
Section 6 – Appendix 48
Methodology 48
Ratio Definitions 48
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Tables
Karyopharm Therapeutics Inc, Key Facts 6
Karyopharm Therapeutics Inc, Key Employees 7
Karyopharm Therapeutics Inc, Key Employee Biographies 8
Karyopharm Therapeutics Inc, Major Products and Services 9
Karyopharm Therapeutics Inc, History 10
Karyopharm Therapeutics Inc, Subsidiaries 14
Karyopharm Therapeutics Inc, Key Competitors 20
Karyopharm Therapeutics Inc, Ratios based on current share price 21
Karyopharm Therapeutics Inc, Annual Ratios 22
Karyopharm Therapeutics Inc, Annual Ratios (Cont...1) 23
Karyopharm Therapeutics Inc, Interim Ratios 25
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28
Karyopharm Therapeutics Inc, Recent Deals Summary 29
Currency Codes 48
Capital Market Ratios 48
Equity Ratios 49
Profitability Ratios 49
Cost Ratios 50
Liquidity Ratios 50
Leverage Ratios 51
Efficiency Ratios 51